A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)
NCT07459556 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2026-03-09
Summary
This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.
Conditions
- SAR
Interventions
- BIOLOGICAL
-
Stapokibart
subcutaneous injection
Sponsors & Collaborators
-
Chengdu Kangnuoxing Biopharma,Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-31
- Primary Completion
- 2027-12-31
- Completion
- 2028-02-29
Countries
- China
Study Locations
More Related Trials
-
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT07146126 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Novel Biologic Therapy for Perennial Allergic Rhinitis
NCT03360071 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
NCT06315426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults
NCT06861101 ·Status: COMPLETED ·Phase: PHASE2
-
AllerPops Reduce Nasal Symptoms in Adult Volunteers With Allergic Rhinitis
NCT05956691 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects
NCT01171664 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
NCT00854360 ·Status: COMPLETED ·Phase: PHASE2
-
Study In Adults And Adolescents With Seasonal Allergic Rhinitis
NCT00115622 ·Status: COMPLETED ·Phase: PHASE3
-
Study of GW685698X In Patients With Seasonal Allergic Rhinitis
NCT00363740 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
NCT07091357 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
NCT00574704 ·Status: COMPLETED ·Phase: PHASE2
-
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)
NCT01024608 ·Status: COMPLETED ·Phase: PHASE3
-
Changes in Specific Immunoglobulin and Blood Basophil Activity During Subcutaneous Immunotherapy in Allergic Rhinitis
NCT01085526 ·Status: COMPLETED ·Phase: NA
-
The Efficacy and Safety of Sanfujiu on Patients With Persistent Allergic Rhinitis: Randomized Controlled Study
NCT02192645 ·Status: UNKNOWN ·Phase: PHASE3
-
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)
NCT00197262 ·Status: COMPLETED ·Phase: PHASE3
-
EWO1 in Persistent Allergic Rhinitis Patients
NCT00153595 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Seasonal Allergic Rhinitis In Pediatric Subjects
NCT00107757 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)
NCT03463031 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
NCT06046391 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of Perennial Allergic Rhinitis
NCT00358475 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
NCT00575003 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT06837233 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of CM310 in Patients With Allergic Rhinitis
NCT05908721 ·Status: COMPLETED ·Phase: PHASE2
-
Study In Adults And Adolescents With Seasonal Allergic Rhinitis.
NCT00225823 ·Status: COMPLETED ·Phase: PHASE3
-
Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination
NCT05009134 ·Status: UNKNOWN